Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
|Videos|November 10, 2017
Are Hospital Mattresses Putting Patients at Increased Risk for C. difficile?
Author(s)Contagion® Editorial Staff
Edmond Hooker, MD, DrPH, discusses multiple factors that put patients at increased risk of getting C. difficile.
Advertisement
Edmond Hooker, MD, DrPH, professor, Health Services Administration at Xavier University, and emergency physician at the University of Cincinnati, discusses multiple factors that put patients at increased risk of getting C. difficile.
Interview Transcript (modified slightly for readability):
"You’re at risk for getting C. difficile infections, if you’re getting antibiotics, if you’re on proton pump inhibitors, if people aren’t washing their hands; those kinds of things have been well recognized. But the big risk to inpatients is the mattress. Patients are exposed to the mattress; they’re lying on it for hours on end, and these mattresses cannot be cleaned and are not being cleaned as we are currently doing it today, and we need to change.”
Advertisement
Related to this article
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Recent urinary tract infection guideline updates from multiple international
medical societies highlight evolving recommendations, including a major shift
in classification, moving from anatomy- and risk factor–based definitions
toward distinguishing localized from systemic infections.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
IDSA/ESCMID panel member Henry Chambers, MD, explains why the new S aureus bacteremia guidance replaces the complicated vs uncomplicated label with risk stratification, and how the statements are akin to the stages of cancer in guiding treatment decisions associated with this bacteremia.
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
Advertisement
Advertisement
Trending on Contagion Live
1
Recent Guideline Updates in the Management of Urinary Tract Infections
2
Clinical Considerations for Measles: Presentation, Treatment, and Hospitalization
3
FAQ: Rising Rabies Exposure Calls PEP Decisions Back in Focus
4
Measles Update: October 2, 2026
5